Skip to content

LeMaitre Vascular LMAT Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Vericel logo
VericelVCEL
Axogen logo
AxogenAXGN
LivaNova logo
LivaNovaLIVN
ICU Medical logo
ICU MedicalICUI

Other financials

Income statement

See full
Revenue$66.6M+11.2%
Gross profit$48.4M+16.8%
Operating income$17.8M+40.8%
Net income$15.7M+42.4%
EPS (diluted)$0.68+41.7%

Balance sheet

See full
Cash & equivalents$26.9M+6.0%
Total debt$20.9M+20.6%
Total equity$406.6M+17.0%
Total assets$629.5M+13.2%

Cash flow

See full
Operating cash flow$15.1M+67.0%
CapEx$2.8M+101%
Free cash flow$12.3M+60.8%

Valuation

See full
Market cap$2.1B+31.4%
Enterprise value$2.1B+31.6%
P/E33.7×-1.7×
P/S8.2×+1.1×

Profitability

See full
Gross margin72.4%+3.6pp
Operating margin28.5%+5.1pp
Net margin24.3%+4.4pp
FCF margin30.9%+12.7pp

Returns & leverage

See full
Return on equity16.5%+2.8pp
Debt / equity0.1×0.0×
Current ratio14.3×-2.2×

Where this comes from

Reported directly by LeMaitre Vascular in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: LeMaitre Vascular’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LeMaitre Vascular's amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LeMaitre Vascular's amortization expense related to capitalized debt issuance costs?
LeMaitre Vascular (LMAT) reported amortization expense related to capitalized debt issuance costs of $222K in Q1 2026.
How has LeMaitre Vascular's amortization expense related to capitalized debt issuance costs changed year-over-year?
LeMaitre Vascular's amortization expense related to capitalized debt issuance costs increased by 4.7% year-over-year, from $212K to $222K.